Last reviewed · How we verify
BP-C2
BP-C2 is a small molecule that targets the renin-angiotensin system to lower blood pressure.
BP-C2 is a small molecule that targets the renin-angiotensin system to lower blood pressure. Used for Hypertension.
At a glance
| Generic name | BP-C2 |
|---|---|
| Also known as | Ammonium molybdate complexed with a lignin-derived polymer containing benzene polycarboxylic acids, molybdenum salts of benzene-polycarboxylic acids |
| Sponsor | Meddoc |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
BP-C2 works by inhibiting the angiotensin-converting enzyme (ACE), which is a key component of the renin-angiotensin system. This leads to decreased levels of angiotensin II, a potent vasoconstrictor, resulting in vasodilation and reduced blood pressure.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- Recommended Dose Estimation of BP-C2 (PHASE1)
- BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BP-C2 CI brief — competitive landscape report
- BP-C2 updates RSS · CI watch RSS
- Meddoc portfolio CI